AL-15469A for the Treatment of Bacterial Conjunctivitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00332293 |
Recruitment Status :
Completed
First Posted : June 1, 2006
Last Update Posted : November 18, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bacterial Conjunctivitis | Drug: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5% Drug: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 695 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India |
Study Start Date : | May 2006 |
Actual Primary Completion Date : | December 2006 |
Actual Study Completion Date : | December 2006 |
Arm | Intervention/treatment |
---|---|
Experimental: Moxifloxacin |
Drug: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%
1 drop into the conjunctival sac of both eyes 3 times a day for 3 days |
Active Comparator: VIGAMOX |
Drug: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
Other Name: VIGAMOX |
- Clinical cure and microbiological success
- Individual signs and symptoms of bacterial conjunctivitis at each visit

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Month and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- signs and symptoms of bacterial conjunctivitis
- Other protocol-defined inclusion criteria may apply
Exclusion Criteria:
- under 1 mo. age
- Other protocol-defined exclusion criteria may apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00332293
United States, Texas | |
Contact Alcon for Trial Locations | |
Fort Worth, Texas, United States, 76134 |
Responsible Party: | Alcon Research |
ClinicalTrials.gov Identifier: | NCT00332293 |
Other Study ID Numbers: |
C-04-40 |
First Posted: | June 1, 2006 Key Record Dates |
Last Update Posted: | November 18, 2016 |
Last Verified: | March 2012 |
Conjunctivitis, Bacterial Conjunctivitis Conjunctival Diseases Eye Diseases Eye Infections, Bacterial Bacterial Infections Bacterial Infections and Mycoses Infections Eye Infections Moxifloxacin Pharmaceutical Solutions Ophthalmic Solutions Norgestimate, ethinyl estradiol drug combination Anti-Bacterial Agents |
Anti-Infective Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Contraceptive Agents, Hormonal Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs Contraceptives, Oral, Combined Contraceptives, Oral Contraceptive Agents, Female |